Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy
To characterise the effects of rituximab on synovial tissue of patients with refractory rheumatoid arthritis (RA). Arthroscopic biopsy of knee joint synovium was performed on 6 patients with seropositive RA prior to commencing rituximab. Four patients underwent repeat biopsy eight weeks following co...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2008-07, Vol.26 (4), p.656-658 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 658 |
|---|---|
| container_issue | 4 |
| container_start_page | 656 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 26 |
| creator | WALSH, C. A. E FEARON, U FITZGERALD, O VEALE, D. J BRESNIHAN, B |
| description | To characterise the effects of rituximab on synovial tissue of patients with refractory rheumatoid arthritis (RA).
Arthroscopic biopsy of knee joint synovium was performed on 6 patients with seropositive RA prior to commencing rituximab. Four patients underwent repeat biopsy eight weeks following completion of their rituximab infusion schedule. Cryostat sections of synovium were prepared and stained with mouse monoclonal specific antibodies including CD20, plasma cell antibody and CD68.
Eight weeks after treatment mean DAS28 fell from 6.6+/-0.43 to 4.7+/-0.49 (p=0.068). Mean CRP fell from 86.7+/-27 mg/L to 20.5+/-7 mg/L (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69586335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69586335</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-c6707fa375397561dfa59dad001307fb0ef7f44c10abb833bee5cb365f22f0d53</originalsourceid><addsrcrecordid>eNo90MFLwzAUBvAgipvTf0Fy0VshTZakOcqmUxh4UditvLYvLto2NWnd9t9bcXp6h-_Hx8c7IdNUGpEwk21OyZQJw5NMqs2EXMT4zhhXUulzMkkzbUzK2JTAEsuAELGiiyVnFPddwBidb6lradji0EDvXUUh9NvgehdpPLT-yw0Ntb6u_c61bzSjO8SPSL2loxn2roGC9lsM0B0uyZmFOuLV8c7I68P9y-IxWT-vnhZ366TjwvRJqTTTFoSWwmip0sqCNBVUjKViDAqGVtv5vEwZFEUmRIEoy0IoaTm3rJJiRm5_e7vgPweMfd64WGJdQ4t-iLkyMlNC_MDrIxyKBqu8C-PccMj_njKCmyOAWEJtA7Sli_-OM5VpzZn4BvPkbVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69586335</pqid></control><display><type>article</type><title>Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>WALSH, C. A. E ; FEARON, U ; FITZGERALD, O ; VEALE, D. J ; BRESNIHAN, B</creator><creatorcontrib>WALSH, C. A. E ; FEARON, U ; FITZGERALD, O ; VEALE, D. J ; BRESNIHAN, B</creatorcontrib><description>To characterise the effects of rituximab on synovial tissue of patients with refractory rheumatoid arthritis (RA).
Arthroscopic biopsy of knee joint synovium was performed on 6 patients with seropositive RA prior to commencing rituximab. Four patients underwent repeat biopsy eight weeks following completion of their rituximab infusion schedule. Cryostat sections of synovium were prepared and stained with mouse monoclonal specific antibodies including CD20, plasma cell antibody and CD68.
Eight weeks after treatment mean DAS28 fell from 6.6+/-0.43 to 4.7+/-0.49 (p=0.068). Mean CRP fell from 86.7+/-27 mg/L to 20.5+/-7 mg/L (p<0.05). Subsynovial CD20+ B cells were demonstrated in all six patients at baseline. B cells were completely depleted in two patients at follow-up biopsy. Complete depletion was associated with excellent clinical response. No change in subsynovial B cells was seen in one patient. One patient's follow-up arthroscopy yielded inadequate tissue. A reduction was also seen in subsynovial plasma cells and CD68+ cells after treatment.
B cells were present in synovial tissue of all patients with refractory RA. Complete depletion of B cells was associated with an excellent clinical response. These preliminary results suggest that early depletion of synovial B cells precedes a decrease in local inflammation leading to clinical improvement.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>PMID: 18799100</identifier><language>eng</language><publisher>Pisa: Clinical and Experimental Rheumatology</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antigens, CD20 - metabolism ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; B-Lymphocytes - immunology ; Biological and medical sciences ; Cohort Studies ; Diseases of the osteoarticular system ; Female ; Humans ; Immunologic Factors - therapeutic use ; Immunomodulators ; Inflammatory joint diseases ; Knee Joint - immunology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Rituximab ; Synovial Membrane - immunology</subject><ispartof>Clinical and experimental rheumatology, 2008-07, Vol.26 (4), p.656-658</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20687720$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18799100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WALSH, C. A. E</creatorcontrib><creatorcontrib>FEARON, U</creatorcontrib><creatorcontrib>FITZGERALD, O</creatorcontrib><creatorcontrib>VEALE, D. J</creatorcontrib><creatorcontrib>BRESNIHAN, B</creatorcontrib><title>Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>To characterise the effects of rituximab on synovial tissue of patients with refractory rheumatoid arthritis (RA).
Arthroscopic biopsy of knee joint synovium was performed on 6 patients with seropositive RA prior to commencing rituximab. Four patients underwent repeat biopsy eight weeks following completion of their rituximab infusion schedule. Cryostat sections of synovium were prepared and stained with mouse monoclonal specific antibodies including CD20, plasma cell antibody and CD68.
Eight weeks after treatment mean DAS28 fell from 6.6+/-0.43 to 4.7+/-0.49 (p=0.068). Mean CRP fell from 86.7+/-27 mg/L to 20.5+/-7 mg/L (p<0.05). Subsynovial CD20+ B cells were demonstrated in all six patients at baseline. B cells were completely depleted in two patients at follow-up biopsy. Complete depletion was associated with excellent clinical response. No change in subsynovial B cells was seen in one patient. One patient's follow-up arthroscopy yielded inadequate tissue. A reduction was also seen in subsynovial plasma cells and CD68+ cells after treatment.
B cells were present in synovial tissue of all patients with refractory RA. Complete depletion of B cells was associated with an excellent clinical response. These preliminary results suggest that early depletion of synovial B cells precedes a decrease in local inflammation leading to clinical improvement.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antigens, CD20 - metabolism</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>B-Lymphocytes - immunology</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunomodulators</subject><subject>Inflammatory joint diseases</subject><subject>Knee Joint - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Rituximab</subject><subject>Synovial Membrane - immunology</subject><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90MFLwzAUBvAgipvTf0Fy0VshTZakOcqmUxh4UditvLYvLto2NWnd9t9bcXp6h-_Hx8c7IdNUGpEwk21OyZQJw5NMqs2EXMT4zhhXUulzMkkzbUzK2JTAEsuAELGiiyVnFPddwBidb6lradji0EDvXUUh9NvgehdpPLT-yw0Ntb6u_c61bzSjO8SPSL2loxn2roGC9lsM0B0uyZmFOuLV8c7I68P9y-IxWT-vnhZ366TjwvRJqTTTFoSWwmip0sqCNBVUjKViDAqGVtv5vEwZFEUmRIEoy0IoaTm3rJJiRm5_e7vgPweMfd64WGJdQ4t-iLkyMlNC_MDrIxyKBqu8C-PccMj_njKCmyOAWEJtA7Sli_-OM5VpzZn4BvPkbVs</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>WALSH, C. A. E</creator><creator>FEARON, U</creator><creator>FITZGERALD, O</creator><creator>VEALE, D. J</creator><creator>BRESNIHAN, B</creator><general>Clinical and Experimental Rheumatology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20080701</creationdate><title>Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy</title><author>WALSH, C. A. E ; FEARON, U ; FITZGERALD, O ; VEALE, D. J ; BRESNIHAN, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-c6707fa375397561dfa59dad001307fb0ef7f44c10abb833bee5cb365f22f0d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antigens, CD20 - metabolism</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>B-Lymphocytes - immunology</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunomodulators</topic><topic>Inflammatory joint diseases</topic><topic>Knee Joint - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Rituximab</topic><topic>Synovial Membrane - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WALSH, C. A. E</creatorcontrib><creatorcontrib>FEARON, U</creatorcontrib><creatorcontrib>FITZGERALD, O</creatorcontrib><creatorcontrib>VEALE, D. J</creatorcontrib><creatorcontrib>BRESNIHAN, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WALSH, C. A. E</au><au>FEARON, U</au><au>FITZGERALD, O</au><au>VEALE, D. J</au><au>BRESNIHAN, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2008-07-01</date><risdate>2008</risdate><volume>26</volume><issue>4</issue><spage>656</spage><epage>658</epage><pages>656-658</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>To characterise the effects of rituximab on synovial tissue of patients with refractory rheumatoid arthritis (RA).
Arthroscopic biopsy of knee joint synovium was performed on 6 patients with seropositive RA prior to commencing rituximab. Four patients underwent repeat biopsy eight weeks following completion of their rituximab infusion schedule. Cryostat sections of synovium were prepared and stained with mouse monoclonal specific antibodies including CD20, plasma cell antibody and CD68.
Eight weeks after treatment mean DAS28 fell from 6.6+/-0.43 to 4.7+/-0.49 (p=0.068). Mean CRP fell from 86.7+/-27 mg/L to 20.5+/-7 mg/L (p<0.05). Subsynovial CD20+ B cells were demonstrated in all six patients at baseline. B cells were completely depleted in two patients at follow-up biopsy. Complete depletion was associated with excellent clinical response. No change in subsynovial B cells was seen in one patient. One patient's follow-up arthroscopy yielded inadequate tissue. A reduction was also seen in subsynovial plasma cells and CD68+ cells after treatment.
B cells were present in synovial tissue of all patients with refractory RA. Complete depletion of B cells was associated with an excellent clinical response. These preliminary results suggest that early depletion of synovial B cells precedes a decrease in local inflammation leading to clinical improvement.</abstract><cop>Pisa</cop><pub>Clinical and Experimental Rheumatology</pub><pmid>18799100</pmid><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2008-07, Vol.26 (4), p.656-658 |
| issn | 0392-856X 1593-098X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69586335 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - metabolism Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology B-Lymphocytes - immunology Biological and medical sciences Cohort Studies Diseases of the osteoarticular system Female Humans Immunologic Factors - therapeutic use Immunomodulators Inflammatory joint diseases Knee Joint - immunology Male Medical sciences Middle Aged Pharmacology. Drug treatments Rituximab Synovial Membrane - immunology |
| title | Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decreased%20CD20%20expression%20in%20rheumatoid%20arthritis%20synovium%20following%208%20weeks%20of%20rituximab%20therapy&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=WALSH,%20C.%20A.%20E&rft.date=2008-07-01&rft.volume=26&rft.issue=4&rft.spage=656&rft.epage=658&rft.pages=656-658&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E69586335%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69586335&rft_id=info:pmid/18799100&rfr_iscdi=true |